Mallikarjuna Rao Balida, Vedavijaya T, Ramani Y Roja, Chowdhury Bimalendu
Pharmacology and Therapeutics, Meenakshi Academy of Higher Education and Research, Chennai, IND.
Pharmacology, Meenakshi Ammal Dental College and Hospital, Chennai, IND.
Cureus. 2024 Nov 21;16(11):e74166. doi: 10.7759/cureus.74166. eCollection 2024 Nov.
Background Diabetes mellitus, characterized by chronic hyperglycemia, often leads to severe hepatic dysfunction, including increased liver enzyme levels and histopathological changes in the liver. Streptozotocin (STZ)-induced diabetic rat models provide a valuable method for evaluating potential therapeutic agents that target hepatic complications. , a medicinal plant with known anti-diabetic properties, has been used traditionally for its hepatoprotective effects, although scientific evidence is limited. Objective This study aimed to evaluate the protective effects of leaf extract on hepatic function, including biochemical and histopathological changes, in STZ-induced diabetic Wistar albino rats. Methods Thirty male Wistar albino rats were randomly divided into five groups: Normal control (NC), diabetic control (DC), low-dose (LD, 200 mg/kg), high-dose (HD, 400 mg/kg), and positive control (PC, metformin 100 mg/kg). Diabetes was induced by a single intraperitoneal injection of STZ (100 mg/kg). treatment was administered daily for 30 days. Blood samples were collected at 15 and 30 days to assess blood glucose and liver function, including serum bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels. Liver tissue was collected for histopathological examination. Data were analyzed using analysis of variance (ANOVA), with p < 0.05 considered statistically significant. Results The DC group showed significantly elevated blood glucose levels (256 ± 19.8 mg/dL at 15 days and 308.5 ± 13.1 mg/dL at 30 days). treatment significantly reduced blood glucose in a dose-dependent manner, with the HD group showing the greatest improvement (143 ± 12.7 mg/dL at 15 days and 158.5 ± 10.7 mg/dL at 30 days). Liver function markers, including total and direct bilirubin, AST, and ALT, were significantly elevated in the DC group, indicating hepatic damage. -treated groups showed significant improvements in all liver function parameters, with the HD group displaying the most substantial reductions in bilirubin, AST, and ALT levels. Histopathological analysis revealed marked hepatocellular damage in the DC group, including necrosis and ballooning degeneration. In contrast, -treated groups, particularly the HD group, exhibited near-normal liver architecture with minimal damage. Conclusion demonstrated significant hepatoprotective effects in STZ-induced diabetic rats by reducing blood glucose levels and improving liver function. These results suggest that could be a promising therapeutic agent for managing diabetes-related hepatic dysfunction.
糖尿病以慢性高血糖为特征，常导致严重的肝功能障碍，包括肝酶水平升高和肝脏组织病理学变化。链脲佐菌素（STZ）诱导的糖尿病大鼠模型为评估针对肝脏并发症的潜在治疗药物提供了一种有价值的方法。[植物名称]是一种具有已知抗糖尿病特性的药用植物，传统上因其肝脏保护作用而被使用，尽管科学证据有限。
本研究旨在评估[植物名称]叶提取物对STZ诱导的糖尿病Wistar白化大鼠肝功能的保护作用，包括生化和组织病理学变化。
将30只雄性Wistar白化大鼠随机分为五组：正常对照组（NC）、糖尿病对照组（DC）、低剂量[植物名称]组（LD，200mg/kg）、高剂量[植物名称]组（HD，400mg/kg）和阳性对照组（PC，二甲双胍100mg/kg）。通过单次腹腔注射STZ（100mg/kg）诱导糖尿病。[植物名称]治疗每天给药30天。在第15天和第30天采集血样以评估血糖和肝功能，包括血清胆红素、天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）水平。收集肝脏组织进行组织病理学检查。数据采用方差分析（ANOVA）进行分析，p<0.05被认为具有统计学意义。
DC组血糖水平显著升高（第15天为256±19.8mg/dL，第30天为308.5±13.1mg/dL）。[植物名称]治疗以剂量依赖性方式显著降低血糖，HD组改善最大（第15天为143±12.7mg/dL，第30天为158.5±10.7mg/dL）。DC组肝功能指标，包括总胆红素和直接胆红素、AST和ALT，显著升高，表明肝脏受损。[植物名称]治疗组所有肝功能参数均有显著改善，HD组胆红素、AST和ALT水平降低最为显著。组织病理学分析显示DC组肝细胞有明显损伤，包括坏死和气球样变性。相比之下，[植物名称]治疗组，尤其是HD组，肝脏结构接近正常，损伤最小。
[植物名称]通过降低血糖水平和改善肝功能，在STZ诱导的糖尿病大鼠中显示出显著的肝脏保护作用。这些结果表明，[植物名称]可能是治疗糖尿病相关肝功能障碍的一种有前景的治疗药物。
